tjh-v38i3

Wang L. et al: Characteristics and Therapy of AML-MRC
Turk J Hematol 2021;38:188-194
5. Yanada M, Suzuki M, Kawashima K, Kiyoi H, Kinoshita T, Emi N, Saito H,
Naoe T. Long-term outcomes for unselected patients with acute myeloid
leukemia categorized according to the World Health Organization
classification: a single center experience. Eur J Haematol 2005;74:418-423.
6. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T,
Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T,
Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF,
Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML
in adults: 2017 ELN recommendations from an international expert panel.
Blood 2017;129:424-447.
7. Jaffe ES, Harris NL, Stein H. Pathology and Genetics of Tumours of
Haematopoietic and Lymphoid Tissues. World Health Organization
Classification of Tumours. Lyon, IARC Press, 2001.
8. Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D’Incan E,
Charbonnier A, Blaise D, Mozziconacci MJ, Vey N. Prognostic significance of
myelodysplasia-related changes according to the WHO classification among
ELN-intermediate-risk AML patients. Am J Hematol 2015;90:E22-24.
9. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J
Med 2015;373:1136-1152.
10. Christman JK. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of
DNA methylation: mechanistic studies and their implications for cancer
therapy. Oncogene 2002;21:5483-5495.
11. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol
2007;61:140-152.
12. Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen
A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G,
Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans PW, Döhner
H. A multicenter phase II trial of decitabine as first-line treatment for
older patients with acute myeloid leukemia judged unfit for induction
chemotherapy. Haematologica 2012;97:393-401.
13. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer
J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl
S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, openlabel,
phase III trial of decitabine versus patients choice, with physician
advice, of either supportive care or low-dose cytarabine for the treatment
of older patients with newly diagnosed acute myeloid leukemia. J Clin
Oncol 2012;30:2670-2677.
14. Liu F, Wang H, Liu J, Zhou Z, Zheng D, Huang B, Su C, Zou W, Xu D, Tong
X, Li J. A favorable inductive remission rate for decitabine combined with
chemotherapy as a first course in <60-year-old acute myeloid leukemia
patients with myelodysplasia syndrome features. Cancer Med 2019;8:5108-
5115.
15. Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR, Villegas L,
Gergis US, Mayer SA, Ippoliti CM, Curcio TJ, Ritchie EK, Feldman EJ. Phase
I study of epigenetic priming with decitabine prior to standard induction
chemotherapy for patients with AML. Blood 2011;118:1472-1480.
16. Jiang X, Wang Z, Ding B, Yin C, Zhong Q, Carter BZ, Yu G, Jiang L, Ye J,
Dai M, Zhang Y, Liang S, Zhao Q, Liu Q, Meng F. The hypomethylating
agent decitabine prior to chemotherapy improves the therapy efficacy
in refractory/relapsed acute myeloid leukemia patients. Oncotarget
2015;6:33612-33622.
17. Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, Wilson
RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi
A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R,
Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K,
Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert
TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. TP53 and decitabine
in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med
2016;375:2023-2036.
18. Ritchie EK, Feldman EJ, Christos PJ, Rohan SD, Lagassa CB, Ippoliti C, Scandura
JM, Carlson K, Roboz GJ. Decitabine in patients with newly diagnosed and
relapsed acute myeloid leukemia. Leuk Lymphoma 2013;54:2003-2007.
19. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S,
Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine
SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-
Calero M, Croce CM, Marcucci G. Clinical response and miR-29b predictive
significance in older AML patients treated with a 10-day schedule of
decitabine. Proc Natl Acad Sci U S A 2010;107:7473-7478.
20. Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A,
Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer
HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der
Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW. Decitabine improves
progression-free survival in older high-risk MDS patients with multiple
autosomal monosomies: results of a subgroup analysis of the randomized
phase III study 06011 of the EORTC Leukemia Cooperative Group and
German MDS Study Group. Ann Hematol 2016;95:191-199.
21. Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, Janoria KG, Gieser G,
Bateman DA, Przepiorka D, Shen YL, Shord SS, Sheth CM, Banerjee A,
Liu J, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R. FDA Approval
Summary: (Daunorubicin and cytarabine) liposome for injection for the
treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res
2019;25:2685-2690.
22. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon
LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC,
Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/
daunorubicin, vs cytarabine/daunorubicin in older adults with untreated
AML. Blood 2014; 123:3239-3246.
23. Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux
A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. Phase
II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin)
liposome injection versus intensive salvage therapy in adults with first
relapse AML. Cancer 2015;121:234-242.
24. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK,
Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE,
Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M,
Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin) liposome
for injection versus conventional cytarabine plus daunorubicin in older
patients with newly diagnosed secondary acute myeloid leukemia. J Clin
Oncol 2018;36:2684-2692.
25. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M,
Ashton JM, Pei S, Grose V, O’Dwyer KM, Liesveld JL, Brookes PS, Becker
MW, Jordan CT. BCL-2 inhibition targets oxidative phosphorylation and
selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell
2013;12:329-341.
26. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt
O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J,
Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine
in treatment-naive, elderly patients with acute myeloid leukemia. Blood
2019;133:7-17.
27. Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A,
Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T,
Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ. Venetoclax
combined with low-dose cytarabine for previously untreated patients
with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol
2019;37:1277-1284.
28. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva
M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J,
Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K,
Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia.
N Engl J Med 2020;383:617-629.
29. National Comprehensive Cancer Network. Clinical Practice Guidelines
in Oncology: Acute Myeloid Leukemia. Plymouth Meeting, NCCN, 2020.
Available online at https://www.nccn.org/professionals/ physician_gls/pdf/
aml.pdf.
194